E-pharmacy

1 audited teardown. Data first, narratives last.

Fintech (24)D2C (12)E-commerce (7)Consumer (3)Direct-to-Consumer (3)EdTech (3)Mobility (3)NBFC (3)Audio Streaming (2)Consumer Electronics (2)Diagnostics (2)F&B (2)Healthcare (2)Insurtech (2)P2P Lending (2)Quick Commerce (2)Auto-Tech (1)B2B (1)B2B Seafood (1)E-pharmacy (1)Edtech (1)Entertainment (1)Furniture Rental (1)Health & Wellness (1)Health Tech (1)Hospitality (1)Logistics (1)Manufacturing Marketplace (1)Payments (1)Rental Marketplace (1)Roll-Up (1)SaaS (1)Silver Jewelry (1)Social Media (1)Used Car Marketplace (1)Wealth Management (1)

Tata 1mg

Tata 1mg's Standalone Made ₹65 Cr Profit. The Group Lost ₹271 Cr.

Tata 1mg's standalone audit reports a profitable ₹65 Cr year. The consolidated audit for the same period reports a ₹271 Cr loss. Both are from the same filing. The standalone is the parent entity (Tata 1mg Technologies Pvt Ltd) charging intercompany platform, IP, and services fees to its operating subsidiaries; revenue at that layer is ₹375 Cr. The consolidated includes the operating pharmacy business, where end-customer revenue is ₹2,353 Cr, inventories of ₹177 Cr sit on the balance sheet, and the cumulative cost of running the e-pharmacy operation is visible. Borrowings grew ₹290 Cr year-on-year at the group level; property additions jumped 12x to ₹123 Cr. The consolidated net worth is -₹352 Cr; this is structurally an accounting representation of accumulated group losses against Tata Digital's equity contribution, not a distress signal.

8 min read

Read →